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This review focuses on the prodrugs used in suicide gene therapy. These prodrugs need to satisfy a number of criteria. They must
be eﬃcient and selective substrates for the activating enzyme, and be metabolized to potent cytotoxins preferably able to kill cells at
all stages of the cell cycle. Both prodrugs and their activated species should have good distributive properties, so that the resulting
bystander eﬀects can maximize the eﬀectiveness of the therapy, since gene transduction eﬃciencies are generally low. A total of 42
prodrugs explored for use in suicide gene therapy with 12 diﬀerent enzymes are discussed, particularly in terms of their physioco-
chemical properties. An important parameter in determining bystander eﬀects generated by passive diﬀusion is the lipophilicity of
the activated form, a property conveniently compared by diﬀusion coeﬃcients (logP for nonionizable compounds and logD7 for
compounds containing an ionizable centre). Many of the early antimetabolite-based prodrugs provide very polar activated forms
that have limited abilities to diﬀuse across cell membranes, and rely on gap junctions between cells for their bystander eﬀects. Sev-
eral later studies have shown that more lipophilic, neutral compounds have superior diﬀusion-based bystander eﬀects. Prodrugs
of DNA alkylating agents, that are less cell cycle-speciﬁc than antimetabolites and more eﬀective against noncycling tumor cells,
appear in general to be more active prodrugs, requiring less prolonged dosing schedules to be eﬀective. It is expected that continued
studies to optimize the bystander eﬀects and other properties of prodrugs and the activated species they generate will contribute to
improvements in the eﬀectiveness of suicide gene therapy.
INTRODUCTION
Gene-directed enzyme-prodrug therapy (GDEPT) or
suicide gene therapy is comprised of three components;
the prodrug to be activated, the enzyme (usually nonhu-
man) used for activation, and the delivery system for the
corresponding gene [1]. Most attention to date has been
directed towards development of the vector systems, on
whichthereisalargeliterature.Thisreviewfocusesonthe
small molecule prodrugs used in such therapies. Prodrugs
can be considered as comprised of two major domains; a
“trigger” unit that is the substrate for the activating en-
zyme, and an “eﬀector” unit that is activated or released
by this metabolic process, sometimes joined by a deﬁn-
able linker [2]( Figure 1).
As well as being an eﬃcient and selective substrate for
theactivatingenzyme,theprodrugitselfneedstobeasys-
temic agent, metabolically stable and able to diﬀuse eﬃ-
ciently by paracellular and/or transcellular routes to the
areas in the tumor where the activating enzyme is be-
ing generated. The eﬀector that is activated or released
from the prodrug must be an eﬀective cytotoxin (prefer-
ably able to kill cells at all stages of the cell cycle), but
must also have good bystander eﬀects (an ability to dif-
fuse to and kill neighbouring tumor cells). Most delivery
TRIGGER LINKER EFFECTOR
selective
metabolism
deactivate
eﬀector
potent & diﬀusible
cytotoxi
Figure 1. Trigger-linker-eﬀector concept for prodrug design.
systems still have very low eﬃciencies of gene transduc-
tion, and the bystander eﬀect of the eﬀector species is im-
portant in compensating for this [3]. The physicochem-
ical properties that govern these desirable pharmacoki-
netic characteristics of both prodrugs and eﬀectors are
beginning to be understood, and include molecular size,
overall lipophilicity, charge, rate of metabolism, and the
propensity to form reversible or irreversible complexes
with cellular macromolecules.
Thenextsectionprovidesabriefoverviewofprodrugs
that have been explored for use in GDEPT, and their cor-
responding eﬀectors. These are grouped according to the
activating enzyme, and do not provide extensive details
of relative levels of use but focus on the chemistry of the
prodrugs. Table 1 provides a broad categorization of the
DNA binding of the prodrugs (and their activated forms)2003:1 (2003) Prodrugs for Suicide Gene Therapy 49
Table 1. Estimated physicochemical properties governing the bystander eﬀects of GDEPT prodrugs and their principal eﬀectors.
Prodrug Eﬀector
No logP
a DNAb No logP
a DNAb
1a (GCV) −2.07 low 1b −6.70c low
2a (E-GCV) 7.0 low 1b −6.70c low
3a (PCV) −2.03 low 3b −6.71c low
4a (ACV) −1.76 low 4b −6.34c low
5a (VCV) −0.78 low 4b −6.34c low
6a (BVDU) −0.43 low 6b −5.25c low
7a (AZT) −0.58 low 7b −5.46 low
8a (MCT) −1.77 low 8b −6.49c low
9a (5-FC) −1.79c low 9b (5-FU) −2.17c low
10a (MEP) −0.35 low 10b 0.09c low
11a (FAMP) −2.32 low 11b −1.26c low
12a (CPA) 0.23 low 12b −3.95c bondd
13a (IFO) 0.50 low 12b −3.95c bondd
14a 0.34 low 14b (NABQI) 0.38 bondd
15a (4-IM) 0.70 low unknown — bondd
16a (CMDA) −4.67c low 16b 0.05 bondd
17a −3.09c low 17b 1.66 bondd
18a −1.62c low 18b 3.73 bondd
19a ∼ 3.0 high 19b (DOX) 0.34c high
20a (MTX-Phe) 2.74 low 20b (MTX) −0.28 low
21a (IRT) 1.54c low 21b (SN-38) 2.02 low
22a 2.04c high 22b 1.51c bondd
23a (CB1954) 1.28 low 23b −0.34 bondd
24a (SN23862) 2.06 low 24b 2.50 bondd
29a 4.40 medium 29b 4.13 medium
32a 4.55 medium 32b 1.87 bondd
35a (IAA) −0.81c low 35b 1.35 high
36a (FIAA) −1.09c low 36b 1.80 bondd
37a (6-TX) −0.41c low 37b −5.52c low
38a (HM1826) 1.53 high 19b 0.36c high
39a 0.78 high 22b 1.51 bondd
40a 0.78 high 22b 1.51 bondd
41a (5 -DFUR) −0.82 low 9b −2.17c low
42a (SeMET) −3.15c low 42b 0.72d,e low
a Calculated using Advanced Chemistry Development (ACD) Software 5.0 package.
b Estimate (based on structure only) of the level of reversible binding to DNA.
c logD at pH 7 for compounds with ionizable groups.
d Covalent alkylation of DNA.
e Calculated for S analogue.
discussed here, based on the knowledge of their structure.
Most have little or no ability to bind reversibly to DNA,
some are likely to have signiﬁcant binding constants, and
many (especially the activated forms) can covalently react
with DNA. Since both reversible and irreversible binding
lower the free drug concentration that drives diﬀusion,
the level of DNA binding can signiﬁcantly inﬂuence the
bystander eﬀect. The lipophilicity of both the prodrug
and the activated drug also has an important inﬂuence
on bystander abilities [4]. Table 1 contains logP values50 William A. Denny 2003:1 (2003)
(n-octanol/water partition coeﬃcents) for the com-
pounds, calculated using the Advanced Chemistry De-
velopment (ACD) 5.0 Software package. These calculated
values are approximations, and can diﬀer substantially
from measured values in some series, but in the absence
of measured values for most of the compounds serve to
at least rank the compounds overall. For those possessing
ionizable centres, logD7 values are used; these take into
account the logP values of the neutral and ionized forms
and the relative proportions of each at pH 7.
PRODRUGS FOR THYMIDINE KINASE (TK)
Introduction
ThemostprominentGDEPTtherapyhasbeentheuse
of the herpes simplex type-1 thymidine kinase enzyme
(HSV-Tk) in conjunction with a variety of guanosine-
based prodrugs, compounds originally developed as an-
tiviral (anti-herpes) agents [5, 6] .T h ee n z y m ec o n -
verts these prodrugs very eﬃciently (much more eﬃ-
ciently than the corresponding endogenous kinases) to
the monophosphates, which are then converted by cellu-
lar enzymes to the toxic triphosphates (Figure 2). These
cause cell death by inhibition of incorporation of dGTP
into DNA, and also by prevention of chain elongation [7].
Fusion proteins of HSV-Tk with green ﬂuorescent pro-
teinshowedthatenzymeexpressionwaspredominantlyin
the nucleus of both transduced human and rodent glioma
cells [8]. A study using positron-emission tomography
(PET) showed that the extent of gene expression corre-
lated with therapeutic response in glioma [9].
Ganciclovir(GCV;1a)
This is the most widely used prodrug for HSV-Tk,
and is well known in its own right as an antiviral agent
[6]. It is a very hydrophilic compound (calculated logP −
2.07; see Table 1). The HSV-Tk enzyme converts this to
the monophosphate (1b) which can then be converted
by cellular enzymes to the toxic triphosphate (Figure 2).
The high cytotoxicity shown by GCV in HSV-Tk trans-
duced cells is suggested to be due to its enhanced ability,
compared to related prodrugs, to incorporate into DNA
without inhibiting progression through the S-phase [10].
In CHO cells, GCV is a potent inducer of chromosome
breaks and sister chromatid exchange at concentrations
well below those required for its gene therapy activity
[11].
The monophosphate eﬀector 1b is more polar than
GCV even as the neutral form (logP = −2.6), but is also
partially ionized to an anionic species, giving a calculated
partition coeﬃc i e n ta tp H7( l ogD 7)o f−6.7( Table 1). Al-
though this species has very limited ability to cross cell
membranes by passive diﬀusion, HSV-Tk/GCV therapy
demonstrates bystander eﬀects in a number of models.
Numerous studies have shown this is mediated primar-
ily by gap junctional intercellular communication (GJIC)
[7, 12, 13]. Because extensive gap junction networks are
not common in tumors, a variety of methods to augment
HSV-Tk/GCV therapy have been explored [7]. There is
also extensive evidence of an immunological component
to the bystander eﬀect in vivo, in that along with the re-
gression of HSV-tk transduced tumors, distant nontrans-
duced tumors also show signiﬁcant eﬀects [14]. A TH1-
based immune response was seen in rat prostate can-
cer models undergoing HSV-Tk/GCV therapy [15], and
a clinical study also showed elevated numbers of periph-
eralTandBcells,enhancedT-cellactivation,andelevated
serum levels of interleukin 12 during intracranial GCV
treatment [16].
The major clinical use of GCV in GDEPT has been
in glioblastoma, using direct injection of the tumor with
the vector, followed by systemic administration of pro-
drug. The drug is well-tolerated, but there have been var-
ied reports of its utility, including a recent large multicen-
ter stage-III trial on 248 patients with newly diagnosed,
previously untreated glioblastoma multiforme [17]. This
trial found no beneﬁt in either time to tumor progres-
sion nor overall survival time compared to best available
therapy (surgical resection and radiotherapy), attributed
to the poor rate of delivery of the HSV-tk gene, and pos-
sibly poor delivery of the prodrug across the blood-brain
and blood-tumor barriers.
Another approach to improving therapy with GCV is
the use of mutant enzymes. Several studies have showed
that random [18]o rs e m i r a n d o m[ 19]m u t a g e n e s i so f
the wild-type enzyme can provide substantial increases in
both in vitro and in vivo activity, allowing lower and less
immunosuppressive doses of GCV to be used. A number
of mutation sites (eg, at Gln-125 and Ala-168) result in
higher Km values for thymidine binding due to loss of H-
bond contacts, and unaltered or even improved binding
for GCV [20, 21]. This results in reduced competition be-
tween prodrug and thymidine at the active site, providing
improved kinetics of conversion of GCV.
Combination therapy with HSV-Tk/GCV and other
agents have also been explored. Some of these, like pro-
teases such as trypsin or collagenase/dispase [22]a r ed e -
signed to improve gene delivery. Others are designed to
complement the eﬀects of the activated drug, such as
stimulation of the immune system with GM-CSF in [23],
which showed increased cure rates in animal models. Ra-
diation therapy has been used both to upregulate promo-
tors to increase gene expression [24] and to enhance the
cytotoxicity of the activated drug [25]. In HSV-Tk trans-
ducedmouseRM-1prostatecancercells,thecombination
of GCV and radiation was additive at low doses of radi-
ation, and possibly synergistic above doses of 8Gy [26].
Retinoids increase GJIC by induction of connexin expres-
sion, and augment the eﬃciency of cell killing by GCV in
HSV-YK transduced cell lines [27].
A variety of thymidylate synthase inhibitors, in-
cluding Tomudex, 5-ﬂuorouracil (5-FU) and (E)-5-(2-
bromovinyl)-2 -deoxyuridine (BVDU) show synergistic2003:1 (2003) Prodrugs for Suicide Gene Therapy 51
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Figure 2. Activation of ganciclovir and analogues by HSV-Tk.
cell killing when used with GCV in clonogenic assay
studies, while a combination of GCV and 5-FU pro-
vided signiﬁcantly-enhanced survival rates in an sc HT-
29 STK tumor xenograft model in mice [28]. Combina-
tions of GCV and the topoisomerase I inhibitor topote-
can also showed synergistic cell killing in HSV-Tk trans-
duced murine MC38 and human HT-29 colon carcinoma
cell lines in a clonogenic assay, and were superior to GCV
alone in sc tumor xenograft models using the same cell
lines in athymic nude mice [29].
Ganciclovirelaidicacidester(E-GCV;2a)
Thisverylipophilic (logP+7.0) preprodrug ofGCV is
more potent than GCV itself in cell cultures (EC50 for E-
GVC around 2nmol), with a selectivity index (IC50 ratio)
in FM3Atk-/HSV-1tk+ cells of > 2000 fold. Nonspeciﬁc
hydrolysis of the ester gives GCV, and both GCV and E-
GCV were converted to the mono-, di-, and triphosphates
ofGCV.However,thehalf-livesofbothGCVanditsphos-
phate metabolites were much longer (about 50hours) in
cells treated with E-GCV rather than GCV, suggesting the
possible utility of lipophilic preprodrugs for modulating
pharmacokinetics [30].
Penciclovir(PCV;3a)
This prodrug is closely related to GVC, with the ether
replaced by a CH2 group, and has similarly low lipophilic-
ity (logP − 2.03). PCV is less genoxic than GCV or
ACV, inducing sister chromatid exchanges only at cyto-
toxic/apoptotic concentrations, and is only weakly clasto-
genic [11]. Treatment of HSV-Tk transformed baby ham-
ster kidney cells with PCV and GCV, but not ACV, in-
duced rapid accumulation of cells in the S-phase and
apoptotic death as measured by the TUNEL assay [31],
and this property, together with the low genotoxicity of
PCV, makes it a relatively safe alternative drug for suicide
gene therapy [32].
Acyclovir(ACV;4a)
As Zovirax, ACV is the most frequently used antiher-
pes drug. It is closely-related chemically to GCV, but is
slightly more lipophilic (logP − 1.76) due to one less al-
cohol group. ACV is a moderate genotoxin in CHO cells,
inducing chromosomal aberrations and sister chromatid
exchange but only at concentrations much higher than
those achieved in blood plasma in vivo [11]. Comparative
studies have generally shown it to be an eﬀective prodrug52 William A. Denny 2003:1 (2003)
for HSV-Tk, both less toxic and less potent and (perhaps
surprisingly in view of its higher lipophilicity) with lower
bystander eﬀects. However, in a study using ovarian can-
cer cell lines and comparing ACV and GCV at equal con-
centrations, the former showed equal or higher cell killing
eﬃcacy and bystander eﬀects [33]. In other studies using
U251tk human glioblastoma cells stably expressing HSV-
Tk, ACV gave a lesser cell kill than did GCV (< 1.5 log
compared to > 4l o g )[ 10]. As with GCV, ACV sensitizes
HSV-Tk transduced cells to radiation [34]. Clinical stud-
ies of patients with recurrent ovarian cancer treated with
a replication-deﬁcient HSV-tk gene vector, ACV and the
topoisomeraseIinhibitortopotecanshowedmedianover-
all survival comparable to that of patients treated with
conventional chemotherapy [35].
Valacyclovir(VCV;5a)
Valacyclovir is a valine ester preprodrug form of ACV,
which can be given orally. It is relatively lipophilic, al-
though partial ionization of the amine counteracts this to
some extent (logD7 = −0.78). In a clinical study of re-
current ovarian cancer treated with an IP-injected HSV-tk
vector followed by topotecan and either IV ACV or oral
VCV, the levels of ACV and VCV (measured as released
ACV) were similar, suggesting the use of VCV as a cost-
eﬀective alternative in outpatient therapy [36]. Clinical
trials of VCV and a locally-injected replication-deﬁcient
HSV-tk vector in prostate cancer, with [37] or without
[38] concomitant radiation therapy, are in progress.
(E)-5-(2-bromovinyl)-2 -deoxyuridine(BVDU;6a)
This is a potent antiherpes agent recently also used
as a prodrug in gene therapy, and is considerably more
lipophilic than GCV (logP = −0.43). An eﬃcient synthe-
sis has been reported [39]. BVDU exerts its cytotoxic ef-
fect not only by incorporation into replicating DNA, but
also through inhibition of thymidylate synthase. It en-
hances the GCV-induced killing of HSV-Tk transduced
gliomacells[40],althoughBVDUitselfisreportedtohave
a poor bystander eﬀect, both in vitro [41, 42] and in vivo
[43]. It is a particularly good substrate for the varicella
zoster virus thymidine kinase (VSV-Tk). While GCV was
nottoxicinVSV-TktransducedMCF7,T-47D,andMDA-
MB-435 breast cancer cells, BVDU showed high cytotox-
icity (IC50s 600, 100, and 60nmol, respectively) and se-
lectivity indices (IC50 ratios of wild-type to VZV-Tk cells
of400,750,and2000,respectively).Bystandereﬀectswere
notobservedinvitroinMDA-MB-435cells,butwereseen
in 9L rat gliosarcoma cells [44]. BVDU showed radiosen-
sitizing activity in U-251 human glioma cells transduced
with HSV-Tk, giving a sensitization enhancement ratio of
1.9.
Zidovudine(AZT;7a)
While the anti-AIDS drug AZT is a relatively poor
substrate for HSV-Tk, its antimetabolite-type mechanism
of action is similar to that of the guanosine analogues
antiherpes drugs discussed above, and its lipophilicity is
(logP − 0.58) similar to that of BVDU. Genetic modiﬁ-
cation of HSV-Tk produced mutants with reduced speci-
ﬁcity for thymidine and much greater ability to phospho-
rylateAZT,duetoactivesitemutationsthatbetteraccom-
modate the azido group of AZT at the expense of thymi-
dine [45].
2 -Exo-methanocarbathymidine(MCT;8a)
The potent antiviral drug MCT is a substrate for
HSV1-Tk [46], but a better one (12-fold increase in KM)
for the Y101F mutant. Crystal structure studies [47]o f
MCT with both enzymes show that the thymine moiety
of MCT binds similarly to deoxythymidine, with the con-
formationally restricted bicyclo[3.1.0]hexane mimicking
the sugar moiety. In MC38/HSV1-Tk murine colon can-
cer cells, MCT had an IC50 of 2.9µmol (comparable to
thatofGCV),andwasmetabolizedtothemono-,di-,and
triphosphates. Treatment of MC38/HSV1-Tk tumors in
C57/BL6 mice at 100mg/kg twice daily caused complete
inhibition of tumor growth [48].
PRODRUGS FOR CYTOSINE DEAMINASE (CD)
Introduction
AfterHSV-Tk, the cytosine deaminase geneis the next
most widely studied for GDEPT. The enzyme (CD) en-
coded by this gene catalyzes the conversion of cytosine to
uracil, and is an important member of the pyrimidine sal-
vage pathway in prokaryotes and fungi, but is not present
in multicellular eukaryotes. The crystal structure of E. coli
CD has an αβ-8 barrel structure with similarity (struc-
turally not sequence) to adenosine deaminase, but not to
cytidine deaminase [49]. The enzyme is a hexamer, sta-
bilized by domain swapping between enzyme subunits,
and containing the active site in the mouth of the enzyme
barrel. GDEPT therapy using CD has focused almost en-
tirely on one prodrug, the clinically used antifungal agent
5-ﬂuorocytosine.
5-Fluorocytosine(5-FC;9a)
5-Fluorocytosine is a relatively hydrophilic (logP −
1.79) antifungal agent with low toxicity in humans, who
lack an endogenous enzyme that can activate it eﬃ-
ciently. However, bacterial and yeast CD enzymes convert
it eﬃciently to 5-ﬂuorouracil (5-FU) (9b). Studies with
tritiated-5-FC in a human glioblastoma cell line stably
transfected with the E. coli gene for CD showed it entered
the cells relatively slowly by passive diﬀusion, and showed
rapid eﬄux, suggesting that transport of this quite hy-
drophilicprodrugmaybealimitingfactor[50].Theactive
form 5-FC is also quite polar (logD7 − 2.29) but is a dif-
fusible species that is itself the single most eﬀective drug
for colon cancer, being converted by cellular enzymes to
the ribosyl monophosphate 5-FdUMP (Figure 3), which
is an irreversible inhibitor of thymidylate synthetase. An
NMR study of 5-FC in sc yeast CD-transfected human2003:1 (2003) Prodrugs for Suicide Gene Therapy 53
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colorectalcarcinomaxenografts innude micederived rate
constants of 0.49min−1 for CD-catalyzed prodrug con-
version and 0.77min-1 for 5-FU eﬄux from the tumor
volume [51]. In contrast to GCV, the bystander eﬀects
of CD/5-FC therapy do not depend on gap junctional
intercellular communication (GJIC), and very large ef-
fects are seen with both communication-competent and
-incompetent cells [52], mediated by the diﬀusion of 5-
FU. It has been suggested that CD/5-FU therapy in solid
tumor models can generate complete cures if only 4% of
the tumor cell mass express the enzyme [53].
CD/5-FC therapy has been studied, usually with the
E. coli enzyme, in a wide variety of cancers, perhaps
most notably colon using the carcinoembryonic antigen
(CEA) promoter [53, 54]. MDA-MB-231 breast carci-
noma cells transfected with E. coli CD were sensitized
1000 fold to 5-FC in culture, with only 10% of the in-
fected cells needed to induce complete cytotoxicity of in
cocultureswithnoninfectedcells.ScMDA-MB-231breast
carcinoma xenografts in nude mice [55] and intracranial
h u m a ng l i o m ax e n o g r a f t si ns c i dm i c e[ 56]w e r ec o n -
trolled by an intratumoral dose of an adenovirus encod-
ing E. coli CD and systemic 5-FU. Similar studies have
shown the utility of CD/5-FC in hepatic metastases of
colon carcinoma [57] and prostate cancer [58]. Studies
using Saccharomycescerevisiae CD, which has a KM for 5-
FC about 22-fold lower than that of E. coli CD show that
this enzyme also shows superior results in sc HT29 hu-
man colon carcinoma xenografts [59], producing about
15-fold more 5-FU in tumors at the same dose of 5-FC
and greater radiosensitization [60]. When 5-FC/CD and
HSV-Tk/GCV therapies were compared in a variety of in
vivo models, both appeared of similar eﬃcacy in hepato-
cellularcarcinoma[61],butCD/5-FCwasclearlysuperior
in EBV-associated lymphomas [62], renal cell carcinoma
[63], and colorectal carcinoma [64], attributed to its su-
perior bystander eﬀect.
Coexpression of CD together with E. coli uracil phos-
phoribosyltransferase (UPRT), which is absent in mam-
malian cells and which directly converts 5-FU to the 5 -
monophosphate (5 -FdUMP), is synergistic. 9L glioma
cells expressing both enzymes were 375-fold more sen-
sitive to 5-FC than cells transduced with CD alone [65].
Cells expressing both enzymes showed large increases
in5-FdUMP,5-ﬂuorouridinetriphosphate,incorporation
into RNA and inhibition of thymidylate synthase [66].
Coexpression of both CD and HSV-Tk enzymes was also
shown to be synergistic, both in vitro [68] and in sc rat 9L
glioma tumors in nude mice [67] treated with 5-FC and
GCV. The mechanism appears to be an enhancement of
GCV phosphorylation by HSV-Tk following 5-FC treat-
ment [68].
Combination studies of 5-FC with radiotherapy in
CD-transfected tumors also show sensitization of sc
xenografts of squamous cell carcinoma [69], cholangio-
carcinoma [70] and colon carcinoma [71], using a dose
of 800mg/kg/day of 5-FC and from 10–50Gy of tumor
irradiation. Dose-modifying factors of up to 1.5 were ob-
served. A Phase I clinical trial of CD linked to a tumor-
speciﬁc erbB2 promotor in breast cancer patients showed
signiﬁcant levels of expression of the CD gene, restricted
toerbB-2-positivetumorcells,inabout90%ofcases[72].
PRODRUGS FOR PURINE NUCLEOSIDE
PHOSPHORYLASE (PNP)
Introduction
The E. coli purine nucleoside phosphorylase (PNP)
is a hexameric enzyme that catalyzes the reversible phos-
phorolysisof6-amino-2 -deoxyribonucleosidestothefree
base and 2 -deoxyribose-1-phosphates, whereas the cor-
responding (trimeric) human enzyme only hydrolyses
6-oxopurine nucleosides. Comparative crystal structures
show that the active-site location and its overall geome-
try are similar for the E. coli and human enzymes, but the
subunit interactions are quite diﬀerent, with the E. coli
enzyme having more hydrophobic purine- and ribose-
binding sites [73].
6-Methylpurinedeoxyriboside(MEP;10a)
The most widely used prodrug for PNP in GDEPT
is 6-methylpurine deoxyriboside (MEP) (logD7 − 0.35),
which is converted by PNP to more lipophilic (logD7 −
0.09) and highly diﬀusible metabolite 10b (Figure 4).
This has the potential advantages of being less cell cycle-
speciﬁc than most antimetabolites and having excellent
bystander eﬀects. Human ovarian tumors transfected
with E. coli PNP controlled by an SV40 promoter and im-
planted IP were shown to express PNP in only 0.1% of
the cells after 5 days, yet treatment of these with MEP re-
sultedinanaverage49%reductionintumorsizeand30%
increase in life span compared with control tumors [74].
A comparison of MEP/PNP and GCV/HSV-Tk therapy
in a PC-3 human androgen-independent prostate cancer
cell line showed that MEP/PNP caused more rapid cell
killingata5–10-foldlowerinputofvirus[75].Againstthe
samecellsassctumorsinnudemice,bothsystemsshowed
comparable activity, holding tumor growth to about 75%
of that of controls after 52 days, and providing about 20%
of long-term survivors [76].
Fludarabine(FAMP;11a)
Fludarabine (arabinofuranosyl-2-ﬂuoroadenine mono
phosphate), has also been studied as a possible prodrug54 William A. Denny 2003:1 (2003)
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for PNP gene therapy. FAMP showed good activity
against sc D54MG glioma tumor xenografts expressing
E. coli PNP, but was not quite as eﬀective as MEP [77].
Human hepatocellular carcinoma cell lines (HepG2,
Hep3B, and HuH-7) expressing PNP were highly sensi-
tized to FAMP, showing IC50so f< 1µmol, with excellent
bystander eﬀects (better than those for GCV) [78].
T r e a t m e n to fP N P - t r a n s d u c e dH e p G 2a n dH e p 3 Bc e l l s
with FAMP induced p53 accumulation and the rapid
onset of apoptosis, and caused similar levels of killing in
both p53-positive and negative lines. This independence
of FAMP-induced killing on p53 status suggests that
FAMP/PNP may be superior to GCV/HSV-Tk for gene
therapy of human hepatocellular carcinoma [79].
PRODRUGS FOR CYP ENZYMES
Introduction
Prodrugs for gene therapy based on NADH cyto-
chrome P450 (CYP) enzymes are compounds that are
normally activated primarily by one or more of the
many CYP isozymes [80]. The large number of diﬀerent
isozymes, and the fact that many drugs and other xenobi-
otics are metabolized by them, makes the potential choice
of prodrugs quite wide. Many of these enzymes are ex-
pressed to greater extent in liver than in tumor cells, so
the primary goal of this strategy is to selectively increase
tumor cell exposure to cytotoxic drug metabolites by tar-
geting expression of the enzymes to tumor cells by gene
vectors. To date, this area has been dominated by only two
prodrugs, the alkylating agents cyclophosphamide and
ifosfamide, but the range of potential compounds is ex-
panding.
Cyclophosphamide(CPA;12a)
This is the most widely used alkylating agent in
conventional cancer chemotherapy. It is much more
lipophilic than the majority of the antimetabolites dis-
cussed above (logP + 0.23) and works by a diﬀerent
mechanism. It is converted to the active alkylating agent
phosphoramide mustard (12b) via initial hydroxylation
to 4-hydroxycyclophosphamide (hydroxy-CPA) by CYP
enzymes (primarily CYP2B1) in the liver (tumor cells
generally contain only low levels of enzyme). Hydroxy-
CPA is in equilibrium with the open-chain aldophos-
phamide, which undergoes spontaneous elimination to
give acrolein and phosphoramide mustard (Figure 5a).
Phosphoramide mustard is a DNA cross-linking agent
that kills cells in a largely cell cycle-independent man-
ner, and thus CPA has potential advantages over GCV
and5-FC,whicharecellcycle-speciﬁcagents.Whilephos-
phoramide mustard itself is very polar (logD7 − 3.95),
the more lipophilic intermediate CPA metabolites (pri-
marily hydroxy-CPA) do not require cell-cell contact
for a bystander eﬀect, distributing by passive diﬀusion
[81, 82]. Early studies with CPA in gene therapy utilized
both retroviral- and adenoviral-mediated transduction of
glioma cells with CYP2B1, and showed that this sensi-
tized them to CPA both in vitro [83] and in vivo [81].
Protection of transduced cells from CPA-induced cyto-
toxicity with the CYP2B1 enzyme inhibitor metyrapone
showed that this sensitization was a direct consequence of
intracellularprodrugactivation[81].SinceCYP-catalyzed
drug metabolism is dependent on electron transfer from
the ﬂavoenzyme NADPH-P450 reductase, double trans-
duction of rat 9L glioma cells with both enzymes substan-
tially increased tumor cell killing [84], and inhibitors of
NADPH-P450 reductase inhibited the activation of CPA
by CYP enzymes [85, 86].
The use of other CYP isozymes to activate CPA
has been explored. AHH-1 human lymphoblastoid cells
transfected with CYP2C9 were 5-fold sensitized to CPA
compared with the wild-type line (IC50s0 . 8 0a n d
4.1mmol, respectively), and showed a bystander killing
eﬀect. This sensitivity was blocked by the CYP2C9-
speciﬁc inhibitor sulfaphenazole. While the sensitivity en-
hancement is not large, CYP2C9 and CPA may possibly
be useful for GDEPT [87]. In a comparative study, 9L-
rat glioma cells were transfected with six diﬀerent CYP
enzymes; 2B6, 2C8, 2C9, 2C18 (Met385 and Thr385 al-
leles), 2C19, and 3A4 [88]. Greatest sensitization to CPA
was seen with CYP2B6, but CYP2C18-Met was also eﬀec-
tive, despite a very low level of CYP protein expression
(> 60-fold lower than that of 2B6), with substantial fur-
ther increases upon additional transduction with NADH
P450 reductase. In 9L glioma sc tumors transduced with
2B6 or 2C18-Met in immunodeﬁcient mice, the best ef-
fects were seen with concomitant expression of NADH
P450 reductase (growth delays of 25–50 days, compared
with 5–6 days). Transduction of HT29 and T47D human
colon carcinoma cells with CYP2B6 using a retroviral vec-
tor (MetXia-P450) sensitized these cells to CPA, and pro-
duced a substantial bystander eﬀect in 3-D multicellu-
lar spheroid models [89]. Treatment of scid mice bearing
400mm3 sc tumors from 9L glioma cells transduced with2003:1 (2003) Prodrugs for Suicide Gene Therapy 55
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CYP2B6 and NADHP450 reductase with CPA (140mg/kg
every 6 days) achieved eradication of 6 out of 8 tumors.
With larger tumors, some resistance to CPA was seen, in-
volving loss of expression of the genes [90].
Ifosfamide(IFO;13a)
Ifosfamide is also used clinically as a conventional
anticancer drug. It is closely related both chemically
and mechanistically to cyclophosphamide, having similar
lipophilicity (logP+0.50) and releasing the same ultimate
metabolite, phosphoramide mustard (12b)( Figure 5a).
Feline kidney cells transfected with CYP2B1 were sensi-
tized to IFO, and killed via necrotic rather than apoptotic
mechanisms [91]. When these cells also expressed cyto-
sine deaminase, additive killing was seen with combina-
tionsofbothIFOand5-FU[92].CYP2B1-transducedhu-
man embryonic epithelial cells implanted in mice bear-
ing human PaCa-44 pancreatic tumor xenografts sensi-
tized these to IP IFO, resulting in partial or even com-
pletetumorablation[93].9Lgliomacellstransducedwith
CYP2B6 and NADPH P450 reductase were sensitized to
both CPA and the bioreductive drug tirapazamine (TPZ)
to the same extent under both normoxic (20% O2)a n d
hypoxic (1% O2) conditions [94]. Under hypoxia, both
CPA and TPZ showed bystander eﬀects, which is surpriz-
ingly given the nature of the highly reactive radical inter-
mediate thought to be the active species of TPZ.
Acetaminophen(14a)
The widely used and relatively lipophilic (logP+0.34)
anti-inﬂammatory drug acetaminophen is oxidized by
the human CYP1A2 enzyme to the cytotoxic metabolite
N-acetylbenzoquinoneimine (NABQI; 14b)( Figure 5b),
which is the major source of toxicity of this drug. Trans-
fection of H1A2 MZ cells with human CYP1A2 sensi-
tized them to treatment with acetaminophen, with the
generation of a substantial bystander eﬀect (complete
killingofV79cellsinamixturecontaining5%transduced
H1A2 MZ cells) [95]. Similar bystander eﬀects were seen
withtransducedSK-OV-3humanovariantumorcellsand
HCT116 human colon tumor cells, but not with MDA-
MB-361 breast tumor cells. Acetaminophen is thus a pos-
sible prodrug for GDEPT in conjunction with CYP1A2.
4-Ipomeanol(4-IM;15a)
4-Ipomeanol is a relatively lipophilic furoketone
(logP + 0.70) that is eﬃciently converted by the rabbit
CYP4B1 enzyme, but not by the corresponding human
isozyme, into toxic DNA-alkylating metabolites of unre-
ported structure [96]. Both rat (9L) and human (U87)
glioma cell lines transduced with rabbit CYP4B1 were
sensitized about 20 fold to 4-IM (IC50sa b o u t2 . 5µmol),
with an eﬃcient bystander eﬀect. Cell killing was associ-
atedwithDNAfragmentation(TUNELassays)andexten-
sive protein-DNA crosslinking and single-strand breaks.
In9Lsctumorxenograftsinnudemice,4-IMinducedsig-
niﬁcantgrowthdelays.Similarresultswereseeninarange
of human hepatocellular carcinoma cell lines (Hep3B,
HuH-7, and HepG2) transduced with rabbit CYP4B1 and
treated with 4-IM, except that bystander eﬀects seemed
to be cell-speciﬁc [97]. In a further comparative study
[98], 4-IM treatment of CYP4B1-transduced 9L glioma
cells showed very little bystander eﬀect (much less than
thatshownbyGVC/HSV-Tk).Thustheutilityof4-IMfor
GDEPT needs further clariﬁcation.56 William A. Denny 2003:1 (2003)
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PRODRUGS FOR CARBOXYPEPTIDASES (CP)
Introduction
This enzyme, from various species of Pseudomonas
bacteria, and for which there is no mammalian counter-
part,hasbeeninvestigatedforuseingenetherapybecause
ofitsabilitytocleaveglutamatemoieties[99].Becausethe
substrates for this enzyme are necessarily diacids, it has
been used primarily in ADEPT protocols, where cell ex-
clusion of very polar prodrugs until activation is an added
beneﬁt. However, more recently it has been adapted for
use in GDEPT by being engineered for surface expression
on the cells [100].
4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-
L-glutamicacid(CMDA;16a)
Thevery polar (logD7−4.67) “mixed” chloromesylate
mustardCMDAwasﬁrststudiedasaprodrugforADEPT,
in conjunction with the enzyme carboxypeptidase G2
(CPG2) derived from the bacterium Pseudomonas putida,
which cleaves the glutamate to generate the active car-
boxylic acid species 16b (Figure 6a)[ 99]. However, stud-
ies with human adenocarcinoma cell lines (A2780 and
SK-OV-3) and human colon carcinoma cell lines (LS174T
and WiDr) that expressed CPG2 internally showed en-
hancedsensitivitytoCMDAovercontrollines(11–16fold
for WiDr and SK-OV-3, 95 fold for A2780 and LS174T),2003:1 (2003) Prodrugs for Suicide Gene Therapy 57
showing these diacids do enter cells [100]. Complete cell
killing was achieved with 4–12% of cells expressing the
enzyme, indicating a substantial bystander eﬀect from
the much more lipophilic (logP + 0.05) released aniline
mustard eﬀector 16b. Nevertheless, later work compar-
ingCMDAwithinternally-expressedandsurface-tethered
CPG2 enzymes in the A2780, SK-OV-3, and WiDr cell
lines showed the latter was superior for activating CMDA
[101] .L o w e rl e v e l so fe n z y m ea n ds h o r t e re x p o s u r e s
to prodrug were required for cell killing with surface-
tethered compared to internally-expressed CPG2. The ac-
tivity of CMDA against human MDA-MB-361 breast car-
cinoma xenografts in nude mice correlated with the per-
centage of CPG2-expressing cells, with some cures seen
even with tumors containing 50% wild-type cells, con-
ﬁrming a substantial bystander eﬀect [102].
Hydroxy-andamino-anilinemustards
(eg,17aand18a)
Because the eﬀector 16b released from CMDA is only
a moderately potent cytotoxin (IC50 65µm in LS174T hu-
man colon carcinoma cells [103]), more potent eﬀectors
have been sought. Thus the prodrugs 17a and 18a release
eﬀectors (17b and 18b; Figure 6a) that are up to 70-fold
more potent than 16b (IC50s in LoVo colon carcinoma
cells of 1.8µmol and 0.34µmol, respectively) [103, 104].
These prodrugs showed IC50 diﬀerentials of 12–14 fold
between wild-type and surface CPG2-expressing WiDr
human colon tumor cell lines in culture. The iodomus-
tard glutamate prodrug 18a, already in clinical trial as
a prodrug for ADEPT [105], also showed much greater
IC50 diﬀerentials in surface CPG2-expressing MDA-MB-
361 and WiDr cells than did CMDA (70–450 fold com-
pared to 19–27 fold), and was highly eﬀective against the
MDA-MB-361 xenografts in nude mice [106].
Anthracyclineglutamates
Prodrugs of anthracycline topoisomerase inhibitors
such as doxorubin with glutamate residues directly at-
tached to the glycoside nitrogen were not substrates for
CPG2, so analogues with a 4-benzylcarbamate spacer
group were investigated [107]. These prodrugs (eg, 19a)
undergo 1,6-elimination following cleavage of the gluta-
mate by CPG2 to release doxorubicin (19b)( Figure 6b).
MDA-MB-361 breast cancer cell lines expressing CPG2
intracellularly or tethered to the outer cell membrane
showed about a 10-fold IC50 diﬀerential compared to
wild-type cells [107].
Methotrexateα-peptides(MTX-Phe;20a)
Methotrexate-α-peptides (eg, MTX-Phe; 20a)a r e
prodrugs of methotrexate (MTX; 20b), a potent inhibitor
of dihydrofolate reductase, and a widely used anticancer
drug. Unlike MTX, the prodrugs are poor substrates for
the reduced folate carrier, and thus not taken up by cells,
but can be cleaved to methotrexate by carboxypeptidase
A1(CPGA)(Figure 6c)[108].Thisendogenousenzymeis
normally inactive until trypsin proteolysis of its propep-
t i d e ,b u tam u t a n tf o r m( C P A S T 3 ) ,a c t i v a t e db yu b i q u i -
tously expressed intracellular propeptidases, has similar
prodrug activating properties [109]. Tumor cells retro-
virally transfected with a cell surface tethered version of
CPAST3 were highly sensitized to MTX-Phe, which also
showed an eﬃcient bystander eﬀect (complete cell kill
with < 10% of the cells transduced).
PRODRUGS FOR CARBOXYLESTERASE (CE)
Introduction
The group of enzymes known as carboxylesterases hy-
drolyse esters and some carbamates to their component
acids and alcohols, and are known to activate some clin-
ical anticancer drugs, notably irinotecan [110]a n dK W -
2189 [111].
Irinotecan(IRT;21a)
Irinotecan is a lipophilic (logD7 = 1.54) topo I in-
hibitor that has been used widely clinically as an anti-
cancer drug. It is converted to the active form SN-38 (7-
ethyl-10-hydroxycamptothecin, 21b)i nh u m a n sp r i m a r -
ily by carboxylesterase (Figure 7a). However, human CE
is relatively poor at activating IRT, with rabbit liver CE
being 100–1000-fold more eﬃcient [110]. A 549 human
lung adenocarcinoma cells transfected with the human
carboxylesterase gene driven by the CMV promoter were
able to convert IRT to the active metabolite SN-38, which
showed a substantial bystander eﬀect in cell culture [112].
When the construct was injected directly into established
scA549tumorsinnudemice,treatmentwithIRTresulted
in 30–40% reductions in tumor size compared with con-
trols. A panel of human tumor cell lines transduced with
rabbit liver CE showed high levels of CE activity, and were
sensitized by 11–127 fold to IRT [110]. This protocol has
been studied as a potential purging method in autologous
stem cell rescue for neuroblastoma. Transfection of neu-
roblastoma cell lines (SJNB-1, NB-1691, and SK-N-SH)
by a replication-deﬁcient adenoviral construct containing
rabbit CE resulted in 100% transfection, and sensitized
the cells to IRT by 20–50 fold [113].
Anthracyclineacetals(22a)
Thelipophilicdoxorubicinacetal(22a)(logD 7+2.04)
is a substrate for CE, which hydrolyses it to an interme-
diate hemiacetal that undergoes immediate cyclization to
the cyclic carbinolamine (22b)( Figure 7b)[ 114]. These
anthracycline carbinolamines (or more likely the resul-
tant iminium ion; Figure 7b) are known to be extremely
cytotoxic agents (100–1000-fold more potent than dox-
orubicin itself), probably due to covalent interaction with
DNA. However, the system does not appear to have been
evaluated in CE-transfected cell lines, and it is likely that
compounds like 22a a r et o ou n s t a b l et oa c ta st u m o r -
speciﬁc prodrugs.58 William A. Denny 2003:1 (2003)
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PRODRUGS FOR NITROREDUCTASE (NTR)
Introduction
Enzymesthatmetabolizearomaticnitrogroupsareat-
tractive for GDEPT because of the very large electronic
change that this metabolism generates. Metabolism of a
nitro group (Hammett σp electronic parameter = 0.78)
to the corresponding hydroxylamine 4-electron reduction
product (σp = −0.34) that is normally the major metabo-
lite, or the possible amine 6-electron reduction product
(σp = −0.66) (Figure 1). These are among the largest pos-
sibleincreasesintheelectroniceﬀect(∆σ = 1.12and1.44)
that can be achieved in a single metabolic step [115], and
this substantial change in electron distribution in the pro-
drug can be exploited in a variety of ways to activate the
eﬀector. Nearly, all GDEPT studies with nitroreductases
have used the nfsB gene product of E. coli, an oxygen-
insensitive ﬂavin mononucleotide (FMN)-containing ni-
troreductase (NTR) [116], with a close sequence ho-
mology to the classical nitroreductase of S. typhimurium
[117]. Crystal structure determinations of NTR show it to
be a homodimer with one FMN per monomer, with two
channels leading into the active site [118]. There are rela-
tively few contacts made with the ligand, which may con-
tribute to its observed broad substrate speciﬁcity [119].
NTR eﬃciently reduces aromatic nitro groups to the hy-
droxylamines in a two-step ping pong bi-bi mechanism
[118]. Four broad classes of prodrugs for NTR have been
studied; dinitroaziridinylbenzamides, dinitrobenzamide
mustards, 4-nitrobenzylcarbamates, and nitroindolines,
and most work has been done with the dinitroaziridinyl-
benzamide CB1954.
CB1954(23a)
ThedinitroaziridinylbenzamideCB1954(23a)isarel-
atively lipophilic (logP + 1.54) prodrug that is eﬃciently
reducedbyNTR(kcat = 360min
−1)[117],eﬀectingreduc-
tion of either the 4- or 2-nitro groups to the correspond-
inghydroxylaminesataboutequalrates(Figure 8a).Mod-
elling suggests that the small aziridine residue allows the
drug far enough into the binding pocket that both the 2-
and 4-nitro groups have access to the FMN [118]. The 4-
hydroxylamine(23b)isthenfurthermetabolizedbycellu-
lar acetylation pathways to a cytotoxic DNA interstrand-
crosslinking agent [120]( Figure 8a). CB1954 demon-
strates substantial bystander eﬀects [121], due to the cell-
permeable hydroxylamine metabolite (logP−0.34) [122].
CB1954 shows high selectivity (100–2000 fold) in a vari-
ety of NTR-transfected cell lines, including human ovar-
ian (SKOV-3) [123], colorectal (LS174T), and pancreatic
(SUIT2, BxPC3) [124], with sensitivity correlating closely
with the level of NTR enzyme expression [123].
B1954 also showed excellent bystander eﬀects in vivo,
inducinglonggrowthdelaysofhumanhepatocellularcar-
cinoma and squamous carcinoma xenografts, even when
only a minority of the tumor cells expressed the enzyme
[125]. Treatment of scid mice with Burkitt lymphoma (Ji-
joye) tumors containing 30% NTR-expressing cells with
CB1954 at 20mg/kg/day for 10 days also gave growth in-
hibition, suggesting a substantial bystander eﬀect [126].
However, expression of NTR in the luminal cells of
the mammary gland using the ovine β-lactoglobulin
promoter resulted in rapid and selective killing of
this cell population by CB1954 with minimal eﬀects2003:1 (2003) Prodrugs for Suicide Gene Therapy 59
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Figure 8. (a) Activation of CB1954 by NTR. (b) Activation of SN23862 by NTR.
neighbouringmyoepithelialcells,suggestingthatthetoxic
metabolite does have a ﬁnite diﬀusion range [127].
A Phase I clinical trial of CB1954 without NTR, ad-
ministered IV on a 3-weekly cycle, determined a rec-
ommended IV dose of 24mg/m2. Dose-limiting toxici-
ties at 37.5mg/m2 were diarrhoea and elevation of liver
transaminases, but no marrow suppression or nephrotox-
icity. A Phase I clinical trial of CB1954 in combination
with adenovirus-delivered NTR is in progress in patients
with primary and secondary liver cancer [128].
SN23862(24a)andanalogues
The dinitrobenzamide mustard SN23862 is more
lipophilic than CB1954 (logP = 2.06), and a better sub-
strate for NTR (Kcat1580min−1)[ 129]. Unlike CB1954,
only the 2-nitro group is reduced (possibly because the
larger mustard unit restricts drug entry to the active
site of NTR) to give the lipophilic (logP = 2.50) 2-
hydroxylamine(24b)(Figure 8b)[130].Theinitial reduc-
tive step fully activates the mustard for DNA crosslink-
ing without further metabolism. While mammalian en-
zymeswithnitoreductaseactivitiesexist,inrats,themajor
endogenous reductive pathway is via the 4-nitro group,
giving the 4-hydroxylamine (25) and ultimately the rela-
tively nonpotent tetrahydroquinoxaline (26) as the major
metabolite (Figure 8b)[ 131]. SN23862 [132] and other
mustard analogues [133] are also not substrates for en-
dogenous DT diaphorase, increasing their attractiveness
as NTR prodrugs.
Ar e c e n ts t u d y[ 4] of a series of analogues of 23a
and 24a demonstrated good correlations between the
lipophilicities of the parent prodrugs (measured logP val-
ues)andtheirbystandereﬀects,measuredinboth3-Dcell
multilayer cocultures of NTR+ve and NTR-ve V79 and
WiDR cells, and also in mixed NTR+ve/NTR-ve WiDr tu-
mors in nude mice. This study provides quantitative evi-
dence, in a series of close analogues, of the importance of
lipophilicity in determining the level of bystander eﬀect;
analogues with logP values lower than that of CB1954
showed relatively poor bystander eﬀects.
In a series of analogues of SN23862 where the 4-
nitro group was replaced by other substituents of vary-
ing electronic properties, cytotoxicity in UV4 cell cul-
tures, from added NTR enzyme, correlated roughly with
the electron-withdrawing properties of the 4-substituent
[134]. The 2-amino-3, 5-dinitrobenzamide regioisomer
(27a) of SN23862 was also a substrate for NTR, and was
in fact superior, with a kcat of 4540min−1 [129]. Compar-
ative cell line studies with SN23862 and the regioisomers
27a and 28a in NTR-transfected Chinese hamster-derived60 William A. Denny 2003:1 (2003)
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Figure 9. Activation of 4-nitrobenzyl carbamates by NTR.
cell lines showed that regioisomeric changes are per-
mitted, with the all three retaining selective cytotoxic-
ity. Finally, analogues with other leaving groups (bromo-
and iodo-mustards) retain good selectivity for the NTR-
transfected line together with higher potency [135].
4-Nitrobenzylcarbamates
Despite their low reduction potential of around
−490mV [136], 4-nitrobenzyl carbamates are substrates
forNTR,beingreducedtothehydroxylamineswhichthen
undergo spontaneous fragmentation to release an amine-
based eﬀector (Figure 9)[ 137]. Electron-donating sub-
stituents on the benzyl ring accelerate the fragmentation
step[138].Thissystemistheoreticallyveryﬂexible,and4-
nitrobenzyl carbamates of a number of diﬀerent classes of
cytotoxic amines have been explored as potential GDEPT
prodrugs [139].
4-Nitrobenzyl carbamate prodrugs (29a,30a)o fD N A
major groove alkylating pyrrolo[2,1-c]benzodiazepines
(29b)[ 140], and of DNA minor groove alkylating tal-
limustine mustards (30b)[ 141] showed diﬀerential cy-
totoxicity towards cells in culture when cotreated with
NTR plus cofactor NADH, but studies have not been re-
ported in NTR-transfected cell lines. The enediyne pro-
drug (31a) showed moderately selective cytotoxicity (135
fold) in the NTR-transfected WiDr human colon carci-
noma cell line [142]. Nitroheterocyclic carbamate trigger
units have also been reported. The 2-nitroimidazole car-
bamate prodrug (32a) of an amino-duocarmycin eﬀector
(32b) was 20-fold more toxic to NTR-transfected SKOV-3
human ovarian carcinoma cell line over the wild-type
[143],extendingthetypesoftriggerunitsthatcanbeused
for this purpose.
Quinones
QuinonescanbeexcellentsubstratesforNTR(thekcat
formenadioneis4.2×104 min−1 comparedwith360min−1
for CB1954) [117], but this is not universal; mitomycin2003:1 (2003) Prodrugs for Suicide Gene Therapy 61
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Ci sap o o rs u b s t r a t e[ 129]. The quinones EO9 (33a)
andAZQ(34a)(Figure 10)generateDNA-reactivespecies
when reduced, but were less than three-fold more cyto-
toxic in NTR-transfected V79 cells compared to wild-type
cells [144].
PRODRUGS FOR HORSE-RADISH PEROXIDASE (HRP)
Introduction
HRP is an iron-containing heme peroxidase that is
well known to oxidize a variety of phenols and amines,
including indole-3-acetic acid, without requiring added
hydrogen peroxide as a cofactor. The mechanism of oxi-
dation by HRP has been widely studied, and shown to in-
volve a series of free radical intermediates of varying iron
oxidation levels [145].
Indole-3-aceticacid(IAA;35a)
Indole-3-acetic acid, a catabolite of tryptophan and
a plant growth hormone, is relatively nontoxic to mam-
malian cells. It is oxidized by HRP, initially to a nitrogen-
centred radical-cation species that rapidly fragments via
a carbon-centred benzyl radical. However, both of these
radical species are extremely short-lived, and unlikely
to account for the observed bystander eﬀects of IAA.
The 3-methylene-2-oxindole (35b)( Figure 10), derived
from the hydroperoxide of the benzyl radical by an un-
clear pathway, has been suggested as the active diﬀusing
species, able to react with DNA [145]. This is suﬃciently
long-lived to generate a bystander eﬀect, and suﬃciently
lipophilic (logP+1.35) to diﬀuse rapidly by passive diﬀu-
sion [146]. HRP transfection eﬀectively sensitized human
T24 bladder carcinoma cells to IAA under both normoxic
and anoxic conditions. IAA also elicted a signiﬁcant, se-
lectiveenhancementofradiation-mediatedcytotoxicityin
T24 cells transiently transfected with the HRP, showing
sensitizer enhancement ratios (SER) ranging from 2.6 to
5.4 [147].
5-Fluoroindole-3-aceticacid(FIAA;36a)
This prodrug is related to IAA, and despite being less
rapidly oxidized by HRP to the corresponding eﬀector
(36b) (rate constant 3.8 × 102 mol
−1sec−1 compared to
3.8×103 mol−1sec−1 forIAA)ismorecytotoxicthanIAAin
a range of HRP-transfected human and rodent tumor cell
lines [148]. Plasma levels of 1mmol and tumor levels of
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Figure 11. Activation of 6-thioxanthine by GPT.
200µmol of FIAA were seen in mice bearing murine car-
cinoma NT tumors, after IP administration of 50mg/kg
FIAA.
PRODRUGS FOR GUANINE RIBOSYLTRANSFERASE
(XGRPT)
Introduction
TheE.coligpt geneencodesaxanthine-guanine phos-
phoribosyl transferase (XGRPT) that has various xan-
thine and guanine analogues as substrates [149].
6-Thioxanthine(6-TX;37a)
6-Thioxanthine (37a) is a relatively nontoxic com-
pound (it is a catabolite of the clinically used an-
timetabolite 6-thioguanine), and is a substrate for E. coli
XGRPT, being converted to the toxic ribophosphate (37b)
(Figure 11). Rat C6 glioma cells retrovirally transduced
with E. coli XGRPT were more than 20-fold sensitized to
6-TX (IC50 of 2.5µmol compared to > 50µmol) [149].
It showed only a weak bystander eﬀect in mixed cocul-
tures [150], which is not unexpected in view of the very
hydrophilic (logD7 − 5.52), charged nature of the phos-
phorylated active species 37b. The prodrug was moder-
ately active in intracerebral C6 glioma xenografts in nude
mice, with an 80% reduction in intracerebral tumor vol-
ume and a 28% increase in mean survival, following in-
tratumoral injection of 6-TX [150].
PRODRUGS FOR GLYCOSIDASE ENZYMES
Introduction
Glycosidase enzymes have been used mostly in
ADEPT,becausetheirveryhydrophilicsugar-bearingsub-
strates show slow cell uptake. However, as with the case
of the CPG2 enzyme, studies with secreted forms of β-
glucuronidase and β-galactosidase show that these en-
zymes can also be used for GDEPT, in conjunction with
anthracycline-basedprodrugs.BothhumanandE.colien-
z y m e sh a v eb e e nu s e d .
HM1826(38a)
OVCAR-3 cells transfected (using a cationic lipid
transfecting agent) with plasmids encoding E. coli-o rh u -
man β-glucuronidase were equally sensitized to both the62 William A. Denny 2003:1 (2003)
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Figure 12. Activation of anthracycline by glycosidases.
glucuronide prodrug DOX-GA3 and the eﬀector doxoru-
bicin produced from it (Figure 12), suggesting good up-
take and conversion of the prodrug, but the bacterial en-
zyme was more eﬃcient. Studies with mixed cell cul-
tures showed a strong bystander eﬀect [151]. However,
most work has been done using secreted [152]o rs u r f a c e -
tethered [153] forms of the enzymes, with prodrugs such
as HMR1826 (38a). Despite the high DNA binding of the
released doxorubicin eﬀector 19b, moderate to good by-
stander eﬀects were reported in culture and in vivo.
Anthracyclineacetals
As noted in “Anthracycline acetals”, anthracycline
carbinolamines such as 22b are extremely potent cyto-
toxins, probably because of their spontaneous conver-
sion to iminium ions that can alkylate DNA. The glu-
curonide and galactosyl prodrugs (39a and 40a,r e s p e c -
tively) are substrates for E. coli β-glucuronidase and β-
galactosidase, from which that release the carbinolamine
22b (see Figure 7). In cell culture they were about 104-
and 106-fold more toxic respectively to human A375
melanoma cells in the presence of the enzymes [154, 155]
(see also “Anthracycline acetals”). While this is only a
simple assay (the activating enzymes would need to be
surface-tethered in a GDEPT application because of the
very hydrophilic prodrugs), the very large diﬀerential cy-
totoxicity is noteworthy.
PRODRUGS FOR THYMIDINE PHOSPHORYLASE (TP)
Introduction
The endogenous enzyme thymidine phosphorylase
(TP), which is reported to occur to a greater extent
in tumor cells than in normal tissue, is a monomeric
55-kd enzyme that dephosphorylates thymidine and
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Figure 13. Activation of 5 -DFUR by TP.
related pyrimidine antimetabolites such as 5 -deoxy-5-
ﬂuorouridine [156].
5 -Deoxy-5-ﬂuorouridine(5 -DFUR;41a)
LS174T human colon carcinoma cells transfected
with the human TP gene were up to 40-fold sensitized
to 5 -DFUR, which is converted to 5-FU (10b)b yT P
(Figure 13). The degree of sensitization correlated with
the extent of expression of TP, and in the cocultures a by-
stander eﬀect was seen that did not require cell-cell con-
tact [156]. Transfection of PC-9 human lung adenocar-
cinoma cells with platelet-derived endothelial cell growth
factor (identical to human TP) resulted in a 50-fold in-
crease in levels of enzyme expression, and sensitized them
to both 5 -DFUR and tegafur [157]. MCF-7 breast cancer
cells transfected with the TP had up to 165-fold increased
sensitivity to 5 -DFUR (but not to 5-FU) in culture, and
substantial bystander eﬀects [158].
PRODRUGS FOR METHIONINE-α,γ-LYASE (MET)
Introduction
Many tumors are methionine-dependent, and show
elevated levels of methionine synthesis [159]. Thus2003:1 (2003) Prodrugs for Suicide Gene Therapy 63
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Figure 14. Activation of selenomethionine by MET.
the enzyme methionine-α,γ-lyase, which degrades the
amino acid methionine to ketobutyrate, ammonia,
and methylthiol, has been of therapeutic interest, and
xenografts expressing the MET gene from Pseudomonas
putida grow more slowly than wild-type tumors [160].
Selenomethionine(SeMET;42a)
Selenomethionine (SeMET) is a relatively toxic and
very polar (logD7 − 3.15) analogue of the natural amino
acid methionine, and is a substrate for MET which con-
verts it to ketobutyrate, ammonia, and the moe lipophilic
methylselenol (42b)( Figure 14). Cells transduced by
the adenovirus-delivered MET gene from Pseudomonas
putida showed up to a 1000-fold increase in sensitivity to
SeMET, and showed a strong bystander eﬀect [160]. The
enzyme converts SeMET to methylselenol, which dam-
ages mitochondria by oxidative stress (production of su-
peroxide and other reactive oxgyen species), resulting in
the release of cytochrome c and activation of the caspase
cascade and apoptosis. SeMET inhibited the growth of
MET-transfectedrathepatomaN1S1ascitesinnudemice,
showing substantial delays in body weight gain due to
growth of the tumor ascites [160].
CONCLUSIONS
There are many issues to be considered in the choice
of prodrugs for a particular activating enzyme. While the
most obvious are the high turnover by the enzyme and
thelargediﬀerentialcytotoxicitybetweentheprodrugand
theactivatedform,anotherimportantearlyconsideration
was to select compounds (eg, GCV, 5-FU, CPA, IRT) that
were already in clinical use. This avoided the regulatory
diﬃculties associated with the combination of a new ther-
apeutic agent and a new activating technology.
Also of importance is the nature of the cytoxicity of
theactivateddrug.Mostoftheearlyprodrugsreleasedan-
timetabolites that act only on cycling cells. However, clin-
ical solid tumors are slow-growing and contain hypoxic
regions, resulting in considerable proportions of noncy-
cling tumor cells. This requires prolonged dosing with
cell cycle-speciﬁc agents to ensure high tumor cell killing.
Thus there has been increasing interest (“Prodrugs for
CYP enzymes,” “Prodrugs for Carboxypeptidases (CP)”,
and “Prodrugs for Nitroreductase (NTR)” sections) in
prodrugs that release DNA cross-linking agents, a class
of cytotoxins that are less cell cycle-speciﬁc. The poten-
tial advantage of these compounds is shown by the fact
that single dose protocols can provide curative eﬀects in
tumor xenograft models [4].
Later studies have also drawn attention to the impor-
tance of the maximizing bystander eﬀects, and this review
hasfocusedontheimportanceofthelipophilicity, charge,
and macromolecular binding of both prodrugs and their
eﬀectors(Table 1).Suicidegenetherapyisapromisingbut
very complex technology, and to be broadly clinically use-
ful will require maximization of the therapeutic proper-
ties of all of the components. We are slowly learning how
to do this for the prodrugs.
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